MEMPHIS, Tenn.--(BUSINESS WIRE)--Wright Medical Group, Inc. (NASDAQ: WMGI) today announced that Kevin D. Cordell has been appointed President, U.S. Extremities, effective September 29, 2014. Mr. Cordell will have operating responsibility for Wright’s U.S. extremities and biologic business, reporting directly to the chief operating officer, and be located at Wright’s corporate headquarters in Memphis.
Pascal Girin, Wright’s executive vice president and chief operating officer stated, “For over 20 years, Kevin has led the development, implementation and execution of successful commercial strategies and programs for global medical device, biotech and pharmaceutical companies. His proven track record of success and his passion for building high performing commercial organizations will serve us well as we continue to focus on accelerating revenue growth, driving sales rep productivity gains in our U.S. foot and ankle business, and launching new products, in particular our new INFINITY ankle.”
Prior to joining Wright Medical, Mr. Cordell served as Vice President of Sales for the GI Solutions business at Covidien, a leading global healthcare products company, from May 2012 to September 2014. While at Covidien, he also served as Vice President of Sales & Global Marketing for its Peripheral Vascular business from July 2010 to May 2012. He joined Covidien in July 2010 through the acquisition of ev3 Inc., where he served as Vice President of U.S. Sales from January 2009 to July 2010. Prior to ev3, Mr. Cordell served as Vice President, Global Sales of FoxHollow Technologies, Inc. from March 2007 to October 2007. Earlier in his career, Mr. Cordell also held various positions of increasing responsibility for Johnson & Johnson’s Cordis Cardiology and Centocor companies. He received his bachelor’s degree in finance from the University of Oklahoma.
Robert Palmisano, Wright’s president & chief executive officer commented, “Kevin is an accomplished senior executive with a demonstrated history of leading direct sales organizations and developing fast-growing, underpenetrated markets, and I’m delighted to welcome him to the Wright management team. His deep experience and strong capabilities will be instrumental as we continue to drive our success in our U.S. extremities and biologics markets.”
About Wright Medical
Wright Medical Group, Inc. is a specialty orthopaedic company that provides extremity and biologic solutions that enable clinicians to alleviate pain and restore their patients’ lifestyles. The company is the recognized leader of surgical solutions for the foot and ankle market, one of the fastest growing segments in medical technology, and markets its products in over 60 countries worldwide. For more information about Wright Medical, visit www.wmt.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements,” as defined under U.S. federal securities laws, concerning, among other things, the potential for Mr. Cordell’s skills and experience to be readily transferable to our business and to positively impact our key metrics such as revenue growth, sales productivity and new product launches. These statements reflect management’s current knowledge, assumptions, beliefs, estimates, and expectations and express management’s current view of future performance, results, and trends. Forward-looking statements may be identified by their use of terms such as anticipate, believe, could, estimate, expect, intend, may, plan, predict, project, will, and other similar terms. Forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to materially differ from those described in the forward-looking statements. The reader should not place undue reliance on forward-looking statements. Such statements are made as of the date of this press release, and we undertake no obligation to update such statements after this date. Risks and uncertainties that could cause our actual results to materially differ from those described in forward-looking statements in this press release include the risk that for any reason Mr. Cordell’s skills and experience do not produce the positive effects on our business we presently anticipate. Additional risks and uncertainties are discussed in our filings with the Securities and Exchange Commission (including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2013, and as may be supplemented in our Quarterly Reports on Form 10-Q).
